A new study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable ...

A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy.

A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop ...

Beam Therapeutics Inc. BEAM announced that the FDA has cleared the investigational new drug (IND) application to begin ...

Discover how RNA therapeutics are reshaping medicine, offering new treatments for previously undruggable targets.

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

AccurEdit Therapeutics today announced that its innovative in vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA).

US FDA clears Everest Medicines’ IND application for tumour-associated antigen vaccine, EVM14: Shanghai, China Tuesday, March 25, 2025, 15:00 Hrs [IST] Everest Medicines, a biop ...

Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today reported its financial ...

SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...